HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Prospective trials, society guidelines offer new insights into cancer-associated thrombosis
-
- Should anticoagulation for cancer-associated thrombosis extend beyond 6 months?
- TGIF 2018: The gut and immune function Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Cancer survivorship care has ‘crucial impact’ on patients’ overall well-being David L. Jennings II, MSN, RN, AGPCNP-BC
- Tumor subtype, location should guide MRI surveillance after soft tissue sarcoma excision Christopher N. Johnson, DO; Matthew J. Thompson, MD
- Carotid space lesions: Added value of 68Gallium-DOTATATE PET/MRI Munir Ghesani, MD, FACNM; Ana M. Franceschi, MD
- Brentuximab vedotin before, after chemotherapy improves survival for older patients with Hodgkin lymphoma
- Brentuximab vedotin, nivolumab combination appears active for Hodgkin lymphoma
- Collaboration bridges gap between patients supportive oncology care
-
- Opioid use steady among younger patients with sickle cell disease
- Ramucirumab reduces risk for progression in certain gastric cancers
- Robot-assisted thoraco-laparoscopic esophagectomy reduces complications
- Nivolumab plus ipilimumab demonstrates clinical benefit for certain metastatic colorectal cancers
- Liquid biopsy test detects early-stage colorectal cancer
- Invasive fungal infections uncommon among children with acute lymphoblastic leukemia
- Voxelotor improves hemoglobin levels, hemolysis markers in sickle cell disease
- Engineered stem cells may provide ‘universal’ donor cells for sickle cell disease
-
- Tisagenlecleucel induces durable responses in relapsed, refractory DLBCL
- Duvelisib extends PFS in relapsed or refractory chronic lymphocytic leukemia
- 'Future looks bright' for combination of venetoclax, obinutuzumab in chronic lymphocytic leukemia
- Chronic graft-versus-host disease triples risk for morbidity, frailty among transplant survivors
- Dual HER-2 therapy with trastuzumab, lapatinib improves EFS
- Study reveals genetic differences in recurrent vs. primary tumors
- Ribociclib improves PFS in younger women with advanced breast cancer
- Temporary ovarian suppression preserves fertility during chemotherapy
-
- Trabectedin maintains safety, efficacy for older patients with advanced soft tissue sarcoma
- PTSD common after cancer diagnosis
- Chemotherapy use declines in early-stage breast cancer
- Long-term birth control use reduces risk for ovarian, endometrial cancers
- Survivors of head, neck cancer more likely to die of competing causes
- Childhood chemotherapy may decrease cognitive function in young adults
- Educational video improves hairdressers’ ability to detect skin cancer
- Older patients with HIV at higher risk for cancer
-
- Elevated biomarker level postoperatively increases colon cancer recurrence risk
- Certain BRAF mutations improve prognosis in colorectal cancer
- Androgen deprivation therapy does not increase risk for Alzheimer’s disease, dementia
- Older men less likely to receive definitive therapy for prostate cancer
- Surgery extends survival in early-stage lung cancer
- Osimertinib superior to standard first-line treatments for EGFR-mutated lung cancer
- Partial-breast radiotherapy may spare women of ‘physical discomfort, emotional distress’
- FDA approves Lynparza, first treatment for BRCA-mutated breast cancer
-
- FDA approves Opdivo for resected melanoma
- FDA approves Perjeta-based regimen for adjuvant treatment of early breast cancer
- FDA approves Xgeva for prevention of skeletal-related events in multiple myeloma
- FDA clears stereotactic radiotherapy system for breast cancer
- FDA expands approval of Bosulif for chronic myelogenous leukemia
- FDA grants breakthrough designation to Bavencio plus Inlyta for renal cell carcinoma
- FDA grants breakthrough therapy designation to voxelotor for sickle cell disease
- FDA grants orphan drug designation to CG’806 for acute myeloid leukemia
-
- FDA resources can help prescribers better understand biosimilars
- FDA grants priority review to multiple hematology/oncology agents
- Lymphoma specialist named associate director for clinical services at Rutgers Cancer Institute
- Multifacility blood transfusion management program led to $2 million in annual savings
- Multivitamins may reduce risk for chemotherapy-induced peripheral neuropathy
- Pediatric oncologist named executive director of Israel Cancer Research Fund
- Physician-researcher joins Atlantic Health System
- Roswell Park Comprehensive Cancer Center appoints several leaders
-
- Smartphone app helps screen for pancreatic cancer
- CHIP funding renewed for 6 years
- Opioid emergency declarations offer short-term benefit on a ‘slippery slope’